Abstract
Long noncoding RNAs (lncRNAs) have emerged as critical regulators of cellular functions including maintenance of cellular homeostasis as well as the onset and progression of disease. LncRNAs often exhibit cell-, tissue-, and disease-specific expression patterns, making them desirable therapeutic targets. LncRNAs are commonly targeted using oligonucleotide therapeutics, and advances in oligonucleotide chemistry including C2 ribose sugar modifications such as 2′-fluoro, 2′-O-methyl, and 2-O-methoxyethyl modifications; 2′4′-constrained nucleotides such as locked nucleic acids and constrained 2′-O-ethyl (cEt) nucleotides; and phosphorothioate bonds have dramatically improved efficacy of oligonucleotide therapies. Novel delivery platforms such as viral vectors and nanoparticles have also improved pharmacokinetic properties of oligonucleotides targeting lncRNAs. Accumulating pre-clinical studies have utilized these strategies to therapeutically target lncRNAs and alter progression of many different disease states including Snhg12 and Chast in cardiovascular disease, Mirt2 and HOTTIP in sepsis and autoimmune disease, and Malat1 and HOXB-AS3 in cancer. Emerging oligonucleotide conjugation methods including the use of peptide nucleic acids hold promise to facilitate targeting to specific tissue types. Here, we review recent advances in lncRNA therapeutics and provide examples of how lncRNAs have been successfully targeted in pre-clinical models of disease. Finally, we detail remaining challenges facing the lncRNA field and how advances in delivery platforms and oligonucleotide chemistry might help overcome these barriers to catalyze the translation of pre-clinical studies to successful pharmaceutical development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Pierce JB, Feinberg MW (2009) Long noncoding RNAs in atherosclerosis and vascular injury: pathobiology, biomarkers, and targets for therapy. Arterioscler Thromb Vasc Biol 40:2002–2017
Lu D, Thum T (2019) RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nat Rev Cardiol 16(11):661–674
Wu G-C, Pan H-F, Leng R-X et al (2015) Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun Rev 14(9):798–805
Arun G, Diermeier SD, Spector DL (2018) Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med 24(3):257–277
van Haasteren J, Li J, Scheideler OJ, Murthy N, Schaffer DV (2020) The delivery challenge: fulfilling the promise of therapeutic genome editing. Nat Biotechnol:1–11
Wold SMW, Toth K (2013) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13(6):421–433
Shaw AR, Suzuki M (2019) Immunology of adenoviral vectors in cancer therapy. Mol Ther Methods Clin Dev 15:418–429
Kotterman MA, Schaffer DV (2014) Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15(7):445–451
Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713–1722
Ferreira V, Twisk J, Kwikkers K et al (2014) Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 25(3):180–188
Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199(3):381–390
Tse LV, Klinc KA, Madigan VJ et al (2017) Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci 114(24):E4812–E4821
Maheshri N, Koerber JT, Kaspar BK, Schaffer DV (2006) Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24(2):198–204
Milone MC, O’Doherty U (2018) Clinical use of lentiviral vectors. Leukemia 32(7):1529–1541
Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544
Waehler R, Russell SJ, Curiel DT (2007) Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8(8):573–587
Mallick S, Choi JS (2014) Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J Nanosci Nanotechnol 14(1):755–765
Antimisiaris S, Mourtas S, Papadia K (2017) Targeted si-RNA with liposomes and exosomes (extracellular vesicles): how to unlock the potential. Int J Pharm 525(2):293–312
Li S-D, Huang L (2010) Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 145(3):178
Xia Y, Tian J, Chen X (2016) Effect of surface properties on liposomal siRNA delivery. Biomaterials 79:56–68
Wang Y, Miao L, Satterlee A, Huang L (2015) Delivery of oligonucleotides with lipid nanoparticles. Adv Drug Deliv Rev 87:68–80
Kapadia CH, Melamed JR, Day ES (2018) Spherical nucleic acid nanoparticles: therapeutic potential. BioDrugs 32(4):297–309
Gong N, Teng X, Li J, Liang X-J (2018) Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis. ACS Appl Mater Interfaces 11(1):37–42
Haemmig S, Yang D, Sun X et al (2020) Long noncoding RNA SNHG12 integrates a DNA-PK-mediated DNA damage response and vascular senescence. Sci Transl Med 12:eaaw1868
Dowdy SF (2017) Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35(3):222
Ray KK, Landmesser U, Leiter LA et al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376(15):1430–1440
Ray KK, Stoekenbroek RM, Kallend D et al (2019) Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol 4(11):1067–1075
Graham MJ, Lee RG, Brandt TA et al (2017) Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 377(3):222–232
Swayze EE, Siwkowski AM, Wancewicz EV et al (2007) Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35(2):687–700
Burdick AD, Sciabola S, Mantena SR et al (2014) Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides. Nucleic Acids Res 42(8):4882–4891
Shen W, De Hoyos CL, Migawa MT et al (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37(6):640–650
Migawa MT, Shen W, Wan WB et al (2019) Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins. Nucleic Acids Res 47(11):5465–5479
Bianchini D, Omlin A, Pezaro C et al (2013) First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 109(10):2579–2586
Iannitti T, Cesar Morales-Medina J, Palmieri B (2014) Phosphorothioate oligonucleotides: effectiveness and toxicity. Curr Drug Targets 15(7):663–673
Seth PP, Vasquez G, Allerson CA et al (2010) Synthesis and biophysical evaluation of 2′, 4′-constrained 2′ O-methoxyethyl and 2′, 4′-constrained 2′ O-ethyl nucleic acid analogues. J Org Chem 75(5):1569–1581
Seth PP, Siwkowski A, Allerson CR et al (2009) Short antisense oligonucleotides with novel 2′− 4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52(1):10–13
Nielsen PE, Egholm M (1999) An introduction to peptide nucleic acid. Curr Issues Mol Biol 1(1–2):89–104
Gupta A, Mishra A, Puri N (2017) Peptide nucleic acids: advanced tools for biomedical applications. J Biotechnol 259:148–159
Cheng CJ, Bahal R, Babar IA et al (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518(7537):107–110
Montagner G, Bezzerri V, Cabrini G et al (2017) An antisense peptide nucleic acid against Pseudomonas aeruginosa inhibiting bacterial-induced inflammatory responses in the cystic fibrosis IB3-1 cellular model system. Int J Biol Macromol 99:492–498
Wancewicz EV, Maier MA, Siwkowski AM et al (2010) Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue. J Med Chem 53(10):3919–3926
Viereck J, Kumarswamy R, Foinquinos A et al (2016) Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8(326):326ra322
Micheletti R, Plaisance I, Abraham BJ et al (2017) The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 9(395):eaai9118
Zhang J, Yu L, Xu Y et al (2018) Long noncoding RNA upregulated in hypothermia treated cardiomyocytes protects against myocardial infarction through improving mitochondrial function. Int J Cardiol 266:213–217
Hawiger J (2018) Heartfelt sepsis: microvascular injury due to genomic storm. Kardiol Pol 76(8):1203–1216
Kishimoto K, Matsumoto K, Ninomiya-Tsuji J (2000) TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem 275(10):7359–7364
Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG (2007) Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 282(6):4102–4112
Du M, Yuan L, Tan X et al (2017) The LPS-inducible lncRNA Mirt2 is a negative regulator of inflammation. Nat Commun 8(1):2049
Sun F, Yuan W, Wu H et al (2020) LncRNA KCNQ1OT1 attenuates sepsis-induced myocardial injury via regulating miR-192-5p/XIAP axis. Exp Biol Med (Maywood):1535370220908041
Yong H, Wu G, Chen J et al (2020) lncRNA MALAT1 accelerates skeletal muscle cell apoptosis and inflammatory response in sepsis by decreasing BRCA1 expression by recruiting EZH2. Mol Ther Nucleic Acids 19:97–108
Teoh H, Quan A, Creighton AK et al (2013) BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis. Gene Ther 20(1):51–61
Zhang P, Cao L, Zhou R, Yang X, Wu M (2019) The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun 10(1):1495
Zhou H, Wang X, Zhang B (2020) Depression of lncRNA NEAT1 antagonizes LPS-evoked acute injury and inflammatory response in alveolar epithelial cells via HMGB1-RAGE signaling. Mediat Inflamm 2020:8019467
Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58(1):15–25
McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219
Bottini N, Firestein GS (2013) Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 9(1):24–33
Mor A, Abramson SB, Pillinger MH (2005) The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115(2):118–128
Gjertsson I, Laurie KL, Devitt J et al (2009) Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Mol Ther 17(4):632–640
Hu X, Tang J, Hu X et al (2020) Silencing of long non-coding RNA HOTTIP reduces inflammation in rheumatoid arthritis by demethylation of SFRP1. Mol Ther Nucleic Acids 19:468–481
Zhang CW, Wu X, Liu D et al (2019) Long non-coding RNA PVT1 knockdown suppresses fibroblast-like synoviocyte inflammation and induces apoptosis in rheumatoid arthritis through demethylation of sirt6. J Biol Eng 13:60
Adán N, Guzmán-Morales J, Ledesma-Colunga MG et al (2013) Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J Clin Invest 123(9):3902–3913
Tseng CC, Chen YJ, Chang WA et al (2020) Dual role of chondrocytes in rheumatoid arthritis: the chicken and the egg. Int J Mol Sci 21(3):1071
Li G, Liu Y, Meng F et al (2019) LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/mTOR signalling pathway. J Cell Mol Med 23(10):7116–7120
Zhang HJ, Wei QF, Wang SJ et al (2017) LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-kappaB pathway. Int Immunopharmacol 50:283–290
Arun G, Diermeier S, Akerman M et al (2016) Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev 30(1):34–51
Huang L, Damle SS, Booten S et al (2015) Partial hepatectomy induced long noncoding RNA inhibits hepatocyte proliferation during liver regeneration. PLoS One 10(7):e0132798
Papaioannou D, Petri A, Dovey OM et al (2019) The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nat Commun 10(1):1–15
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pierce, J.B., Zhou, H., Simion, V., Feinberg, M.W. (2022). Long Noncoding RNAs as Therapeutic Targets. In: Carpenter, S. (eds) Long Noncoding RNA. Advances in Experimental Medicine and Biology, vol 1363. Springer, Cham. https://doi.org/10.1007/978-3-030-92034-0_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-92034-0_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-92033-3
Online ISBN: 978-3-030-92034-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)